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respectively. In comparison to that our study shows same or no
inferior outcomewhich proves the drug combination is as effective
as thrombolysis.
Conclusion: Inj. Heparin along with DAPT on FMC following acute
MI yields similar results as thrombolysis with signiﬁcant improve-
ment in TIMI ﬂow of the IRA and also signiﬁcant reduction of the
slow ﬂow, no ﬂow or other complications during PPCI.
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in patients with acute coronary
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Background: Triple antiplatelet therapy (TAT) has been found to be
superior to dual antiplatelet therapy (DAT) in patients with acute
coronary syndromes undergoing percutaneous coronary interven-
tion (PCI) with drug-eluting stents (DES).
Methods: A prospective, double blinded, randomized study was
conducted in ACS patients undergoing PCI with DES and control
population without any coronary artery disease (CAD). ACS
patients were randomized into DAT group (DAT, aspirin + clopido-
grel) and TAT group (TAT, aspirin + clopidogrel + cilostazol).
Patients in the TAT group were given loading doses of 200 mg of
cilostazol peri-procedurally (within 6–12 h prior to the procedure to
1–2 h post-procedure) followed by 100 mg/day for atleast six
months. Patients were evaluated at baseline, at seven days and
six months intervals for clinical outcomes. ADP, collagen, and
epinephrine-induced platelet aggregation was measured at base-
line and at seven days interval.
Results: There were no signiﬁcant differences in the baseline
characteristics in both the groups. Comparison between dual
and triple antiplatelet groups showed signiﬁcantly greater inhibi-
tion of ADP-induced platelet aggregation in the triple therapy
group at seven days interval (19.05  14.06% vs 36.20  25.0%,
p = 0.02) and trend towards greater platelet inhibition at baseline
between two groups (19.2  27.32% vs 33.0  22.01%, p = 0.077),
respectively. Triple therapy group had lesser number of patients
who had hyporesposiveness to antiplatelet therapy (deﬁned as
inhibition of less than 50% of ADP, collagen or epinephrine induced
platelet aggregation). The study was underpowered for assessing
MACE outcomes.
Conclusions: Cilostazol is a signiﬁcant add on therapy to standard
DAT with aspirin and high maintenance dose clopidogrel. Its
loading dose of 200 mg, followed by 100 mg BD provides greater
inhibition of ADP-induced platelet aggregation without increase in
bleeding complications or tolerance issues.
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The objective of this study is to evaluate outcome of the 20 patients
who underwent alcoholic septal ablation for symptomatic HOCM
at our hospital.
Background: LVOT obstruction is an important determinant of
clinical symptoms in patients with HOCM. Alcohol septal ablation
shown to decrease LVOT gradient and resolution of symptoms
immediately after the procedure and on midterm follow-up.
Methods: 20 patients with HOCM who underwent alcoholic septal
ablation at our hospital and completed one-year follow-up are
described. A detailed analysis of clinical examination and Echo
Doppler carried out.
Results: The mean age of the study group was 54  16 years (range
26–76 yrs). All patients had refractory symptoms before enrolment.
90% patients had NYHA class III/IV symptoms at baseline com-
pared to none at 1 year. Only 20% of patients were either receiving
beta-blockers or CCBs on follow-up. The resting LVOT gradient
decreased from 70  20 mmHg to 10  6 mmHg. These changes are
associated with decreased septal thickness and preserved systolic
function. Three patients (15%) developed complete heart block,
two patients improved after TPI and one required permanent
pacemaker. One patient (5%) developed acute anterior wall myo-
cardial infarction and taken for emergency CABG, but died during
post-operatively.
Conclusion: Alcohol septal ablation associated with decreased
septal thickness and preserved systolic function. This procedure
is an effective therapeutic procedure with favorable outcome.
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One hundred patients who underwent PCI with Yukon Choice Flex
(Indigenous stent) between September 2014 to February 2015 have
been studied retrospectively. There were 86 (86%) males and 14
(14%) females with mean age 59.12  12.33 (28–84 years). Risk
factors were hypertension – 50(50%), type 2 DM – 42(42%), smoking
28(28%), CKD 8(8%), and dyslipidemia 14 (14%). Clinical presenta-
tion was ACS with STEMI – 44 (44%), NSTEMI 30 (30%), unstable
angina – 14 (14%). Chronic stable angina was present in 12 (12%)
patients. Mean LVEF of this group was 50.3  9.3% (range 21–60%).
Three patients with STEMI presented in cardiogenic shock.
Coronary angio proﬁle revealed single vessel disease in 54 (54%)
and multi-vessel disease in 46 (46%) patients. PCI was done
through femoral artery in 80 (80%) and right radial in 20 (20%)
patients. Weight adjusted heparin was used as anticoagulant.
Antiplatelet therapy in the form of asprin, clopidogrel, or prasugrel
was used in patients at operators discretion.
Primary angioplasty was done in 16 (16%) patients. IABP support
was used in 6 (6%). GP IIb/IIIa inhibitors were used in 76 (76%)
patients, of which 52 (66%) received tiroﬁban, while 26 (34%)
received abciximab.
All patients received biodegradable polymer sirolimus eluting
Yukon Choice Flex stent. Average stent diameter was 2.92
 0.44 mm. Average stent length was 24.53  8.47 mm. Average
no. of stents deployed per patient was 1.66  0.86. Average dura-
tion of hospital stay was 3  1.31 days. One patient who was in
cardiogenic shock died during the hospital stay. There was no
other MACE during the hospitalization. Two patients were
admitted with subacute stent thrombosis at 7 and 20 days,
requiring re-dilatation. Patients were followed clinically and
telephonically between 6 and 9 months (mean 8.23  7.03
months).
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Conclusion: Preliminary analysis of our data shows encouraging
results with YCF stent in all comer high risk ACS population.
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left main disease with indigenous
sirolinus eluting biodegradable
polymer Yukon choice flex stent
S. Lahiri, P. Nayak, K. Vikram Singh, S. Aijaz Nasir,
A. Govil, T.C. Singh, S.K. Datta, K.K. Sethi *
Delhi Heart & Lung Institute, New Delhi, India
Twenty patients with unprotected left main disease undergoing
coronary angioplasty between January 2013 and August 2015 have
been studied. Therewere 15males (75%) and 5 females (25%),mean
age 63  11 (35–75 years). Risk factors were Type II Diabetes melli-
tus 7 (35%), Hypertension 8 (40%), Smoking 5 (25%), and Dyslipi-
demia 8 (40%). Clinical presentation was ACS with STEMI 3 (15%),
unstable angina 7 (35%), NSTEMI 8 (40%), and stable angina 2 (10%).
Mean LVEF of the group was 35  5%. Three patients with STEMI
presented in cardiogenic shock.
Right femoral artery was accessed in all patients. Weight adjusted
heparin, aspirin and clopidogrel or prasugrel were used as antic-
oagulants and antiplatelets, respectively. IABP was inserted in the
3 (15%) patients with cardiogenic shock due to acute MI. GP IIb/IIIa
receptor blockers were used in all patients. Distribution of disease
in left main: ostial lesion 3 (15%), diffuse shaft disease 2 (10%),
distal bifurcation 12 (60%), trifurcation 3 (15%). Additional triple
vessel disease was seen in 10 (50%).
Technique: Left main to LAD cross over stenting without ﬁnal
kissing – 8 (40%), two stents strategy: TAP 6 (30%), Cullotte 1
(5%), and DK Crush 1 (5%). In one patient, single stent strategy
with simultaneous kissing balloon angioplasty in Cx was done.
Proximal optimizationwas done in all patients. Ostial stentingwas
done in 3 (15%) patients. Procedural success was achieved in all
patients. All patients received DES. 15 patients (75%) received
indigenous Yukon choice ﬂex (Biodegradable polymer) stent, 3
(15%) received Medtronic Endeavor stent and 2 (10%) patients
received Xience stent (Abott). Mean stent diameter in left main
was 4.0  0.53 mm. Mean number of stents per patient was 1.5. In-
hospital mortality occurred in 3 (15%) patients who were in cardio-
genic shock. There was no other MACE or bleeding during hospi-
talization. Patients were followed clinically or telephonically for a
mean duration of 15  6mo (range 4–20mo). Therewere no further
signiﬁcant events during follow-up.
Conclusion: In appropriately selected patients, PCI of unprotected
leftmain gives gratifying results. The performance of Yukon choice
ﬂex (indigenous) stent has been satisfactory. Mortality remains
high in AMI with cardiogenic shock.
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Background: Contrast induced nephropathy (CIN) is a known
complication following coronary angiography and angioplasty.
Rising creatinine levels after coronary procedures is strongly asso-
ciated with poor clinical outcomes. However in clinical practice
there are situations where coronary procedures are necessary for
patients with pre-existing renal dysfunction. There are some clin-
ical suggestion that trimetazidine (TMZ), an anti-ischemic drug,
may prevent CIN.
Methods: To evaluate the efﬁcacy of trimetazidine in the preven-
tion of CIN in patients with pre-existing renal dysfunction under-
going coronary angiography/angioplasty. It was a prospective
single blind randomized trial where 2 groups of patients of class
III angina with serum creatinine values exceeding 1.5 mg/dl were
selected. One group (group A) was administered intravenous (IV)
saline (0.9%) infusion at a rate of 1 ml/kg of body weight for 24 h
starting 12 h before the procedure while the other group (group B)
received 35 mg twice daily of trimetazidine controlled release (CR)
tablet by mouth for 72 h starting 48 h before the procedure in
addition to IV saline infusion like the ﬁrst group. Baseline serum
creatinine was done 24 h before the procedure for enrolment.
Subsequent creatinine values were obtained 1 h before, and 1, 2,
and 7 days after the procedure.
Results: Over a period of 12months fromApril 1, 2014 till March 31,
2015, 140 patients were included in this study. There were 98 male
patients. Mean age was 67  14 years. Forty eight percent had
diabetes, while 34% were hypertensive and 28% were smokers.
Mean serum creatinine was 1.82  0.44 mg/dl. There were 70
patients in group A, who received only saline infusion and remain-
ing 70 were in group B who had both IV saline and oral trimeta-
zidine CR. Age, sex, risk factors, and clinical symptoms were
properly matched in either group. In all nonionic contrast (Iodix-
anol) was used. One day after angiography/angioplasty there was
no signiﬁcant change of serum creatinine in either group. However
on day 2 post-procedure serum creatinine dropped by mean 8.2%
in group A and 9.5% in group B. The difference was not statistically
signiﬁcant. After 7 days of the procedure mean drop of creatinine
was 8.8% in group A and 12.6% in group B. Reduction of serum
creatinine after 7 days of angiography/angioplasty by TMZ therapy
was statistically signiﬁcant.
Conclusions: The addition of trimetazidine to normal saline sig-
niﬁcantly decreased the incidence of CIN in patients undergoing
coronary angiography/angioplasty. In conclusion, trimetazidine
could be considered as a potential tool for prevention of CIN in
patients with renal dysfunction.
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Background: Although conventional 60 mg prasugrel allows for
rapid and potent platelet inhibition within 30 min after loading
dose, the efﬁcacy and safety of lower doses of prasugrel in Indian
patients has not yet been investigated.
Objective: The study sought to compare the efﬁcacy of a lower
loading dose of prasugrel with conventional loading dose of pra-
sugrel in Indian patients.
Material andmethods: 332 Indian patients undergoing elective PCI
were enrolled in the study. Participants were randomly adminis-
tered loading doses of prasugrel 60 mg (group A, n = 166) or 30 mg
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